Special Issue "Liver Cancer and Potential Therapeutic Targets"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 November 2019

Special Issue Editor

Guest Editor
Dr. Hiroyuki Tsuchiya

Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, Nishi-cho 86, Yonago, Tottori 683-8503, Japan
Website | E-Mail
Interests: fatty liver, hepatitis, hepatocellular carcinoma

Special Issue Information

Dear colleagues,

Primary liver cancer, mainly consisting of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, is a leading cause of cancer death worldwide. Recent advances in the development of multikinase inhibitors for the treatment of liver cancer brought us closer than ever to enabling the control or even cure of liver cancer with systemic therapy. However, therapeutic options and efficacy have not sufficiently met clinical demands yet. Furthermore, although prevalent mutations and affected pathways in the course of liver cancer development and progression have been identified, these have not led to therapeutic innovation. Therefore, in order to develop more efficient drugs or to improve current therapies, it is necessary to deepen our understanding of molecular mechanisms underlying liver cancer, and to identify previously unrecognized potential therapeutic targets.

This special issue covers research on molecular mechanisms underlying the development and progression of liver cancer from the viewpoints of diagnosis, prevention and/or therapy. Studies examining the therapeutic efficacy of molecular-targeted drugs or novel therapeutic approaches are also welcomed.

Dr. Hiroyuki Tsuchiya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Perilipin 5 and Lipocalin 2 Expression in Hepatocellular Carcinoma
Cancers 2019, 11(3), 385; https://doi.org/10.3390/cancers11030385
Received: 19 January 2019 / Revised: 13 March 2019 / Accepted: 15 March 2019 / Published: 19 March 2019
PDF Full-text (8111 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly cancers worldwide. Therefore, current global research focuses on molecular tools for early diagnosis of HCC, which can lead to effective treatment at an early stage. Perilipin 5 (PLIN5) has been studied as [...] Read more.
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly cancers worldwide. Therefore, current global research focuses on molecular tools for early diagnosis of HCC, which can lead to effective treatment at an early stage. Perilipin 5 (PLIN5) has been studied as one of the main proteins of the perilipin family, whose role is to maintain lipid homeostasis by inhibiting lipolysis. In this study, we show for the first time that PLIN5 is strongly expressed in tumors of human patients with HCC as well as in mouse livers, in which HCC was genetically or experimentally induced by treatment with the genotoxic agent diethylnitrosamine. Moreover, the secreted acute phase glycoprotein Lipocalin 2 (LCN2) established as a biomarker of acute kidney injury, is also proven to indicate liver injury with upregulated expression in numerous cases of hepatic damage, including steatohepatitis. LCN2 has been studied in various cancers, and it has been assigned roles in multiple cellular processes such as the suppression of the invasion of HCC cells and their metastatic abilities. The presence of this protein in blood and urine, in combination with the presence of α -Fetoprotein (AFP), is hypothesized to serve as a biomarker of early stages of HCC. In the current study, we show in humans and mice that LCN2 is secreted into the serum from liver cancer tissue. We also show that AFP-positive hepatocytes represent the main source for the massive expression of LCN2 in tumoral tissue. Thus, the strong presence of PLIN5 and LCN2 in HCC and understanding their roles could establish them as markers for diagnosis or as treatment targets against HCC. Full article
(This article belongs to the Special Issue Liver Cancer and Potential Therapeutic Targets)
Figures

Graphical abstract

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top